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carcinoma: patient selection and special 
consideration
Ka Wing Ma
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Department of Surgery, Queen Mary 
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Kong, Pok Fu Lam, Hong Kong
Abstract: Localized hepatocellular carcinoma (HCC) refers to a solitary or few tumors located 
within either the left or right hemiliver without evidence of bilobar or extrahepatic spread. This 
term encompasses a heterogeneous morphology with no regard to stage of prognosis of the 
disease. Surgical resection remains the mainstay of curative treatment for the localized HCC. 
Various biochemical and radiological tests constitute an indispensible part of preoperative 
assessment. Emergence of laparoscopic hepatectomy has brought liver resection into a new 
era. Improved understanding of the pathophysiology of HCC allows more aggressive surgi-
cal resection without compromising outcomes. New insights into the management of special 
situations, such as ruptured HCC, pyogenic transformation of HCC, and HCC with portal vein 
tumor thrombus, rekindle the hopes of curative resection in these terminal events. Amalgamating 
salvage liver transplantation into the surgical management of resectable HCC has revolutionized 
the treatment paradigm of this deadly disease.
Keyword: hepatocellular carcinoma, hepatectomy, future liver remnant, transarterial chemo-
embolization (TACE), transarterial radioembolization (TARE)
Introduction
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. 
It is the fifth most common cancer and is ranked the third most common cause of 
cancer-related mortality around the world, leading to over 1 million deaths every 
year.1,2 Majority of the patients present with unresectable disease due to the presence 
of extrahepatic spread, insufficient future liver remnant (FLR), poor liver function, 
performance status, etc. Survival of this group of patients are counted in months 
despite the development of various forms of palliative treatment such as transarterial 
chemoembolization (TACE),3–5 transarterial radioembolization,6 and vascular endo-
thelial growth factor receptor antagonist, also known as sorafenib.7,8 Localized HCC 
does not necessarily infer straightforward management; huge tumor, strategic tumor 
location, major vasculobiliary invasion, rupture of HCC, and pyogenic transforma-
tion are situations that complicate the picture. For the minority of fortunate patients 
who have early disease, liver transplantation (LT) offers the “best chance of cure”, 
with 5-year survival ranging from 70% to 90% depending on different selection 
criteria (Table 1).9–15 However, due to a scarcity of liver graft and stringent selection 
criteria, only a small fraction of these patients can benefit from LT, with almost 90% 
of them having to undergo either ablative therapy or partial hepatectomy. Despite the 
fact that radiofrequency and microwave ablation have been proven to be as effective 
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as  resection for small-sized HCC,16–19 their applicability is 
limited by a number of constraints, such as tumor size (too 
big would risk incomplete ablation), location (too subscapular 
or too deep-seated), and vicinity to vascular (fear of heat 
sink effect), biliary, and hollow organ structure (possible 
collateral damage). At present, liver resection remains the 
mainstay of curative measure due to its availability, flex-
ibility, and inherent efficacy. The overall 5-year survival of 
HCC patients after resection is >50% in most series, and this 
number can be >70% for early disease.20–22 In this article, we 
will go through the technical advances in surgical resection 
of HCC, stratification and selection of patients via different 
investigation modality, and how to deal with special circum-
stances in patients with localized HCC.
Surgical resection for HCC
Liver resection was once considered as an ultra-high-risk 
procedure, and usually resulted in massive blood loss, high 
morbidity, and mortality.23 Until the 1980s, the mortality 
rate of liver resection was still ~10% in many centers.24,25 
Over the last few decades, a multitude of perioperative and 
technical advances have emerged, changing the landscape in 
the field of liver resection. Liver resection can be classified 
into nonanatomical and anatomical resection. The former 
essentially means excision of HCC with a rim of normal 
liver tissue regardless of the location of the tumor; anatomi-
cal resection refers to resection of a specific part of the liver 
according to corresponding pedicle supply and biliary drain-
age. Because most HCC recurrences are intrahepatic and it 
has been postulated that cancer cells spread by microscopic 
invasion and dissemination along portal pedicle,26–28 liver 
resection following its corresponding portal pedicle should 
theoretically maximize oncological clearance.29–32 However, 
this oncological benefit is not demonstrated in some other 
studies.33–38 The reason behind the discrepancy was that, a 
majority of the nonanatomical resections were performed for 
patients with cirrhosis with the hope of conserving the more 
functional liver remnant, and a cirrhotic liver is more prone 
to tumor recurrence due to “field change” and has a worse 
prognosis when compared to the noncirrhotic one; hence, 
it is falsely perceived as the cause of inferior oncological 
outcome. Further well-designed randomized controlled trial 
is needed to properly address this issue.
Besides the controversy of anatomical and nonanatomical 
resection, the surgical approach of hepatectomy has been a 
topic for debate. Since the first laparoscopic hepatectomy 
(LH) performed by Gagner in 1992,39 there has been growing 
enthusiasm to pursue this challenging operative approach 
from all around the world. Initial indication of LH was limited 
to benign diseases of the liver. Thanks to the accumulation of 
experience and reports of encouraging results, the indication 
of LH has been extended to various types of hepatic malig-
nancies, chiefly colorectal liver metastasis and HCC.40–43
The main concerns about laparoscopic hepatectomy 
were oncological clearance and safety issues of this 
approach. However, apart from the inherent benefit of lapa-
roscopic surgery, such as shorter hospital stay,44–47 operation 
time,46,48,49 less analgesic requirement,45 and early resump-
tion of oral intake,45 it has been demonstrated that LH is 
associated with good safety profile, as evidenced by less 
blood loss,46,48–50 and postoperative morbidities and mortal-
ity.46,47,49,51 From the perspective of oncological efficacy, a 
meta-analysis comprising 244 patients with open hepa-
tectomy and 165 patients with LH for liver cancers found 
that there were no significant differences in tumor-free 
resection margin, disease-free and overall survival.52 Sub-
sequent studies confirmed these advantages in the context 
of treating HCC.53–55 Despite the fact that the laparoscopic 
approach has been recommended as the standard of care for 
minor wedge resection and left lateral sectionectomy,56 its 
application in major liver resection was still considered as 
“in exploration phase” due to the complexity of the proce-
dure and the steep learning curve.56,57 With the constantly 
Table 1 HCC survival after liver transplantation from different 
series
Criteria Tumor 
size
Tumor 
number
Additional 
restriction
Overall 
5-year 
survival (%)
UCSF10 <6.5 cm
<4.5 cm
Total <8 cm
Solitary
3 or less
– 75.2
University 
of Tokyo11
≤5 cm 5 or less – 75
Chang Guan 
University12
6.5 cm
4.5 cm
1
3 or less
– 90
Asan13 ≤5 cm 6 or less – 82
Up-to-714 ≤7 7 or less Numerical sum 
of tumor size 
and number 
must be <7
71.2
Hangzhou15 Total size 
≤8 cm
No limit For total tumor 
size >8 cm, 
histological 
grade must 
be I or II and 
AFP must be 
≤400 ng/L
72
Abbreviation: AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; UCSF, 
University of California, San Francisco.
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emerging laparoscopic devices and  effective hemostatic 
 products,58 hurdles in laparoscopic major hepatectomy 
would be overcome in the near future.
Patient selection
As a rule of thumb, careful patient selection is always the key 
to treatment success regardless of the type and approach of 
liver resection used. Treatment options for HCC are largely 
inferred by patient, livers, and tumor factors at presentation 
and these factors form the backbone of a number of well-
adopted treatment algorithms (Table 2).59–63 The association 
between general health condition and prognosis of HCC 
had been well documented.22,59,64–67 In general, patients with 
poor cardiopulmonary function, limited life expectancy, or 
poor quality of life (i.e., bedridden and noncommunicable) 
due to underlying medical comorbidities are not a surgical 
candidate. Liver factors are traditionally assessed by the 
Child–Pugh score.68,69 This score was originally used to 
predict the survival of patients with portal hypertension after 
portosystemic shunt surgery and subsequently was applied 
to predict liver-related mortality of cirrhotic patients. Lack 
of discrimination within the same grade and involvement 
of subjective clinical parameters limit its role in preopera-
tive assessment. Objective biochemical, radiological, and 
metabolic assessments have become the standard practice 
in many centers. Indocyanine green (ICG) is a metabolically 
inert dye. It does not get metabolized or degraded in blood, is 
solely and actively excreted by hepatocytes, and is not reab-
sorbed via the enterohepatic pathway; hence, it is an ideal 
marker for liver function assessment.70–74 ICG is injected at 
a dosage 0.5 mg/kg intravenously; serum retention of ICG 
>15% at 15 minutes is generally considered inadequate75 
although it has been reported that the safety cutoff can be 
as high as 20% for a Child-Pugh A patient.76 The ICG clear-
ance test has become a routine preoperative liver function 
assessment in many centers around the world, and its serum 
level can be checked with pulse spectrophotometry, which 
is faster and not influenced by potential human error dur-
ing serial venous blood sampling.77,78 In addition, the ICG 
disappearance rate and intraoperative ICG measurement 
for the FLR were found to have prognostic implication in 
liver resection and will continue to be a topic of research 
in the future.71,79,80
Apart from biochemical assessment with ICG, volu-
metric assessment of the FLR constitutes an indispensible 
part of the preoperative work-up. With the development 
of helical, multi-detector, thin-slicing CT technology, 
high-quality images can be obtained in just one breath 
holding time, and subsequent FLR volume calculation can 
be done by either an automated or a manual process with 
good accuracy.81,82 The resultant volume is then divided by 
total liver volume (TLV), which is obtained either by CT 
volumetry (after subtraction of tumor volume) or deduced 
from various formulas.83–85 The ratio of FLR volume to TLV 
of 25%–30% for noncirrhotic patients86–88 and up to 40% 
for cirrhotic patients89 are considered safe for hepatectomy. 
In case of situations like the presence of steatosis, fibrosis, 
and cirrhosis, where the liver function might not correlate 
well with the liver volume,90 Technitium-99 mebrofenin 
or galactosyl human serum albumin scintigraphy can be 
used for metabolic assessment of the whole or partial liver 
function.91–93
Table 2 Commonly referred treatment guidelines for HCC
Guidelines Parameters Concept of vascular invasion Tumor staging Resectability
BCLC59 Performance status
Liver function
Tumor status
Invasion of PV branches signifies 
advance disease
Classified as very early, early, 
intermediate, advance and 
terminal
Solitary HCC or <3 tumor 
<3 cm
HKLC60 Performance status
Liver function
Tumor status
Main PV or IVC invasion Early, intermediate or late Early tumor in Child A/B 
cirrhosis
Intermediate in Child A 
cirrhosis
JSH61 Liver function
Presence of vascular 
invasion
Prensece of metastasis
PV invasion classified into Vp1–4 According to TNM stage of 
LCSGJ
Any resectable HCC
APASAL62 Liver function
Presence of vascular 
invasion
Prensece of metastasis
Involvement of main PV or IVC 
branches
3 categories: Resectable, within 
Milan/unresectable within Milan 
and unresectable outside Milan 
criteria
HCC with invasion to sectorial 
branches of PV still be 
considered resectable
Notes: PV tumor invasion was classified into: Vp0, no PV invasion; Vp1, thrombus beyond 2nd order PV branch; Vp2, thrombus at 2nd order branch; Vp3, thrombus at 1st 
order branch; Vp4, thrombus at main PV or involved contralateral PV.
Abbreviations: APASL, Asian Pacific Association for the Study of the Liver; BCLC, Barcelona Clinic for Liver Cancer; HCC, hepatocelluar carcinoma; HKLC, Hong Kong 
Liver Cancer; JSH, Japan Society of Hepatology; LCSGJ, Liver Cancer Study Group of Japan; PV, portal vein; IVC, inferior vena cava.
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The indication and patient selection principle should 
hold true for both open and LH; nonetheless, the decision 
of whether a particular HCC is suitable for laparoscopic 
resection involves a number of considerations. A 10-level 
difficulty index introduced by the Keio University group94 
provides a comprehensive stratification of HCC for pure LH. 
This score takes tumor size, tumor location, extent of resec-
tion, degree of cirrhosis, and proximity to the major vessel 
into account and serves as a useful guide for both patient 
selection and surgeon selection, i.e., operation with high 
difficulty index should only be performed by experienced 
laparoscopic surgeon while those with low difficulty index 
are suitable cases for beginners in LH. For patients with 
large posteriorly situated lesion with high difficulty score, 
use of a hand-assisted or hybrid laparoscopic approach had 
been suggested to reduce the patient risk and need for con-
version.49,95–97 In case the operating surgeon perceives that 
the laparoscopic approach would compromise patient safety 
or oncological outcome, conversion to open hepatectomy 
is indicated.
Special circumstances
Insufficient FLR
Since the development of portal vein embolization (PVE) 
by Makuuchi,98 insufficient FLR is no longer regarded as 
an absolute contraindication for major hepatectomy. This 
technique was originally described for the use in treating 
hilar cholangiocarcinoma,99 and this application had been 
extended to many other primary and secondary hepatic 
malignancies. In the context of HCC, this technique is even 
more relevant as HCC often develops in the background 
of shrunken cirrhotic liver. Studies showed that the 5-year 
survival after resection for patients who had PVE before 
ranged from 50% to 70%, and this is comparable to HCC 
resection without prior PVE.100–103 Besides promoting hyper-
trophy of FLR, this technique also acts as a selection tool 
to screen out patients who are unlikely to survive a major 
hepatectomy due to poor regenerative potential of the liver 
parenchyma and intolerance to portal hypertension after the 
procedure. However, PVE had been criticized of not being 
able to introduce sufficient FLR hypertrophy and possibility 
of disease progression during the 4-week hypertrophy time. 
It has been reported that due to increased arterial supply 
to the tumor-bearing liver during the post-PVE period, the 
tumor growth rate  accelerates due to the hypervascularized 
nature of HCC,104 and the patient dropout rate can be up to 
20%–25%. With the introduction of the new technique of 
associating liver partition and portal vein ligation for staged 
hepatectomy (ALPPS), problems of PVE seem to have been 
well addressed with faster and more FLR hypertrophy. The 
first report of ALPPS from Schnitzbauer found that this pro-
cedure induced liver hypertrophy of 75% in only 9 days.105 
However, in return for the improved resectability, ALPPS 
was noted to be associated with higher morbidity, mortality, 
and higher early recurrence rate.106–108 Though early results 
of ALPPS were promising, these issues need to be clarified 
before this technique can gain further acceptance to become 
a standard of practice.
Ruptured HCC
Ruptured HCC is associated with poor prognosis and its 
incidence varies geographically, from 10% in some Asian 
countries109,110 to <5% in the Western world.110 According to 
the tumor-node-metastasis staging, seventh edition,111 rup-
tured HCC was classified as T
4
 disease. While, some people 
considered it as a contraindication for curative surgery, the 
others reported that resectability of patients with ruptured 
HCC could be up to 12%–33%.110,112–114 We have recently 
analyzed the surgical outcomes of patients with ruptured 
HCC undergoing liver resection and found that the 1-, 3-, 
and 5-year overall survivals were 66%, 37%, and 22.3%, 
respectively, which is statistically worse than nonruptured 
HCC (83.3%, 64.8%, and 53.4% respectively, P<0.001), 
but superior to those who received TACE or systemic 
therapy.61 Therefore, resection should be contemplated for 
patients who have ruptured HCC without overt evidence 
of dissemination.
Portal vein tumor thrombus
HCC has the tendency of invading the portal vein, which 
explains the high incidence of portal vein tumor thrombus 
(PVTT) of ~40%.114 The presence of PVTT in HCC patients 
signifies poor prognosis with median survival of only 2.7 
months if left untreated.115 This tumor thrombus can propa-
gate and lead to complete PV obstruction, causing torrential 
variceal hemorrhage. Treatment for PVTT remained limited, 
and its presence was usually considered a contraindication for 
resection and TACE. Resection is the only possible cure and 
is associated with an operative mortality of 0%–5.9% and the 
median survival ranged from 8.9 to 33 months.116–119 Surgical 
management of PVTT depends on the level of involvement. 
For peripherally located PVTT confined to the ipsilateral 
first-generation portal vein, hepatectomy is recommended. 
Treatment options for PVTT extending to or beyond portal 
vein bifurcation include en-bloc resection and thrombectomy. 
Although portal vein en-bloc resection seems to give a sense 
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of better oncological clearance, majority of the literatures did 
not find a significant difference in survival benefit between the 
two.118,120–122 Preoperative TACE had been proposed and was 
able to achieve 5-year survival in 45% of selected patients.123 
However, these encouraging results  could not be repeated by 
others.121,123 Efficacy of some newer adjuvant therapies such 
as sorafenib7 and infusion of platinum-based chemotherapy 
via hepatic artery124 are areas for further exploration.
HCC with bile duct tumor thrombus
Bile duct tumor thrombus (BDTT) is an uncommon occur-
rence in the context of HCC. It happens in 0.53%–13% of the 
HCC patients.125–127 Prognosis of HCC with BDTT is worse 
than HCC without BDTT.128–130 This difference was thought 
to be related to a more aggressive tumor biology evidenced by 
higher proportion of coexisiting lymphovascular invasion in 
patients with BDTT.131 Preoperative drainage is occasionally 
required in case of severe cholestasis or cholangitis, and can be 
done by endoscopic retrograde cholangiopancreatography or 
percutaneous transhepatic biliary drainage. Tumor thrombus is 
easily retrievable with balloon used for stone extraction due to 
its necrotic and friable nature. Although Ueda classification132 
could be used as a guide for calculating the extent of hepa-
tectomy, our previous analysis131 suggested that radical hepa-
tectomy with extrahepatic bile duct resection was associated 
with better outcome. A 5-year overall survival of 38.5% with 
zero bile duct recurrence was achieved using this approach.
HCC with abscess formation
The reported incidence of de novo pyogenic transformation 
of HCC is ~1%.133 The manifestations of HCC complicated 
by liver abscess include pyrexia, right upper abdominal 
pain, right pleural effusion, and leukocytosis. Portal pyemia, 
ascending cholangitic sepsis, and hemotological inoculation 
of bacteria in a necrotic tumor are some postulated etiol-
ogy.134,135 There has been no standardized management for 
this rare entity; upfront hepatectomy for HCC with abscess 
formation was not recommended due to the reported higher 
morbidity, mortality, and worse oncological outcomes.133 Early 
involvement of microbiologist and interventional radiologist 
is advisable; hepatectomy should be performed in a patient 
with sepsis under control and general conditions optimized 
so as to minimize the above-mentioned adverse outcomes.
Surgical resection as a bridging therapy 
to LT
LT has been the best curative treatment for HCC within 
certain criteria. The 5-year survival of HCC patients after 
LT can be up to 90% in certain series.12 However, due to 
graft shortage and disease progression, a 43% dropout rate 
for HCC patients on a waiting list had been reported.136 The 
concept of salvage transplantation was introduced in 2000 
by Majno et al137 in which they advocated that HCC patients 
should proceed with resection first whenever possible and 
embark on LT only when recurrence developed. This strategy 
would relieve tension in donor pool by postponing the time 
of LT and even reducing the number of LT, as some of the 
patients might not develop HCC recurrence after resection. 
While salvage LT had been recognized as an incorporated 
part of HCC management,138 opponents of the policy of sal-
vage transplant worried that liver transplantation following 
previous hepatectomy might impair transplantability and 
increase the operative risk due to the presence of adhesion 
and distorted anatomy; compromised long-term survival of 
salvage transplant patients was also a concern.139 We had 
previously reported that there was no significant difference 
in long-term survival between HCC patients treated by 
upfront resection or primary LT, provided that the factor of 
microvascular invasion is adjusted,140 and when there is HCC 
recurrence, salvage LT gives the best 5-year model for end-
stage liver disease-adjusted survival in comparison to repeat 
resection and ablation.141 Therefore, localized HCC should be 
resected whenever possible, especially in the region of low 
organ donation rate. Salvage LT should be reserved for any 
unresectable HCC recurrence.
Conclusion
With the advances in various preoperative biochemical and 
radiological assessments, the safety profile of hepatectomy for 
HCC has drastically improved. Situations such as insufficient 
FLR and PVTT that were once considered not amendable to 
surgical resection have now become resectable. Increased under-
standing of special conditions like HCC rupture, abscess trans-
formation, and the role of salvage LT allows better choice of 
treatment and improves long-term outcomes for HCC patients.
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